Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(lymphocyte immune globulin)
148,193 results
  • Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report. [Journal Article]
    BMC Med Genet 2019; 20(1):157Li M, Chen W, … Chen W
  • CONCLUSIONS: This study reported the first written record of a Chinese XLA patient with metastatic CRC and severe hypocalcemia. Whole exome sequencing and bioinformatic analysis indicated the somatic mutations in ABCA6, C6 and PAX3 genes might contribute to the early-onset and metastasis CRC. Besides, a number of germline mutations in genes related to calcium metabolism (CACNA2D4, CD36, etc.) and the administration of irinotecan were speculated to be the causes of severe hypocalcemia. We therefore suggested that in order to avoid severe DRT, clinicians should take genetic background and therapeutic drug monitoring into consideration while planning chemotherapy treatment for XLA patients with CRC.
  • T Cell Profile After Systemic Steroid Burst in Inner-City Asthmatic Children with Recurrent Infections. [Journal Article]
    Pediatr Allergy Immunol Pulmonol 2019; 32(2):56-62Poowuttikul P, Taki M, … Secord E
  • CONCLUSIONS: Frequent systemic corticosteroid use may suppress T cell number and function in asthmatic children. This can potentially lead to increase susceptibility for future infections and asthma exacerbations. Depressed lymphocyte proliferations are observed even in patients who demonstrated normal T cell counts. This emphasizes the importance of adherence to asthma controller medications, and control of asthma triggers, to limit the frequency of steroid use.
  • Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. [Journal Article]
    J Immunother 2019Finkel I, Sternschuss M, … Israel Lung Cancer Group
  • The existing data with regard to immune-related neutropenia (irN), a rare (incidence-1%) immune-related adverse event of immune checkpoint inhibitors, are scarce. Eight patients with irN were identified through internal databases of 3 participating Israeli cancer centers. In addition, 11 original articles focusing on the clinical course of 24 patients with irN were selected during the PubMed sear…
  • The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. [Journal Article]
    Recent Results Cancer Res 2020; 214:169-187Paschen A, Schadendorf D
  • Treatment of patients with advanced metastatic melanoma has for decades been a story of very limited success. This dramatically changed when therapy with anti-PD-1 checkpoint blocking antibodies was approved in the USA and Europe in 2014 and 2015, respectively. The therapy exploits the capacity of CD8+ T cells to specifically kill tumor cells. Within the tumor microenvironment, CD8+ T cell activi…
  • Clinical Experience with Bispecific T Cell Engagers. [Review]
    Recent Results Cancer Res 2020; 214:71-91Gökbuget N
  • Bispecific T cell engagers are antibody constructs directed to a tumor-specific target on the one hand and to CD3-positive T cells on the other hand. Blinatumomab is a compound with specificity for the pan-B cell marker CD19. Clinical activity was tested in relapsed and refractory (R/R) non-Hodgkin's Lymphoma (NHL), R/R acute lymphoblastic leukemia (ALL), and ALL patients with minimal residual di…
  • Hypertension: An immune related disorder? [Journal Article]
    Clin Immunol 2019; :108247Sereti E, Stamatelopoulos KS, … Evangelopoulos ME
  • Hypertension is a multifactorial disorder with serious complications and unknown etiology. Among potential contributors, immune dysregulation has been also proposed. The study population included 61 consecutive hypertensive patients and 55 healthy individuals of similar age and sex distribution. All study participants underwent a thorough evaluation for subclinical atherosclerosis. A full immunol…
  • [Development of innovative T-cell immunotherapy for hematological malignancies]. [Review]
    Rinsho Ketsueki 2019; 60(7):824-833Ochi T
  • With the emergence of cancer immunotherapy, T cells have played important roles in inducing antitumor responses. Many types of antitumor receptors, which possess tumor-binding sites and T-cell activation sites, have been developed. For example, genetically engineered T-cell receptor, chimeric antigen receptor, and bispecific antibody can help us to educate and activate T cells specific for certai…
New Search Next